Tag Archives: HEA

PR Newswire

On-Device AI Healthcare Company Noul Announces 2 Clinical Performance Studies at Pan-African Malaria Conference

Leave a comment

  • miLab showed almost equivalent to WHO-certified first-degree microscopy experts: Sensitivity of 94.4%, Specificity of 98.1%
  • African authority on malaria diagnosis said “miLab is a potential game changer in accelerating access to parasitological confirmation”

YONGIN, South Korea, April 25, 2024 /PRNewswire/ — Noul Co., Ltd., (376930.KR), an On-Device AI healthcare company, announced that the results of a clinical performance study of its malaria diagnostic solution showed a sensitivity of 94.4%, and a specificity of 98.1%, which is almost equivalent to WHO-certified first-degree microscopy experts.

[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria
[Poster] Analytical Performance Experimentation assessment of the miLab™ MAL Malaria system for the detection of Plasmodium falciparum in clinical samples in Lagos, Nigeria

Noul participated in the Multilateral Initiative on Malaria Pan-African Malaria Conference (MIM PAMC) held in Kigali, Rwanda from April 21 to 27, and reveals two of the latest clinical performance studies conducted with its malaria diagnostic solution ‘miLab™ MAL’, in three major African countries, Nigeria, Ethiopia, and Ghana, through a poster presentation.

The study was conducted to verify the effectiveness of miLab™ MAL’s each use-case. And as a result, miLab™ MAL reached a sensitivity of 94.4% and a specificity of 98.1% for P. falciparum diagnosis, and a sensitivity of 97% and a specificity of 97.6% for P. vivax diagnosis. Based on these clinical achievements, Noul plans to actively promote cooperation with global research institutes and the health departments of each country. The achievements through collaborative research are expected to be published as papers within the year. 

Dr. Wellington A.Oyibo, a Chair of the Malaria Operational Research Expert Group of the National Malaria Program (MOREG) and a Professor of Lagos University who directed the research in Nigeria, said “miLab™ MAL is a potential game changer in accelerating access to parasitological confirmation and an asset to malaria control programs. Effective deployment of miLab™ MAL could provide critical data for accurately assessing malaria infection rates and severity, optimizing resource allocation and response strategies. This information is vital for health policymakers to design more effective prevention and case management programs.”

Dr. Taehwan Kim, Managing Director of noul GmbH said, “Africa is a huge single market, accounting for about 20% of the world’s population, and a place with 95.4% of the malaria burden occurring worldwide. By disclosing the excellent clinical performance of our malaria product at the conference involving the entire continent of Africa, we intend to establish specific cooperation relationships with key stakeholders in key markets such as global pharmaceutical companies and international organizations and actively seek new business opportunities.”

Meanwhile, the Multilateral Initiative on Malaria (MIM), established in 1997, is a global alliance of citizens, institutions, funding partners, and members united by the goal of enhancing scientific research capabilities in Africa and controlling and eradicating malaria. The Pan-African Malaria Conference (PAMC) is held every four years, marking its eighth anniversary this year. Major sponsors include the Bill & Melinda Gates Foundation and the Medicine for Malaria Venture (MMV).

About Noul

On-Device Healthcare Company, Noul is recognized for its innovative technology as the first AI-based diagnostic platform company in the blood and cancer sector, with miLab™ platform introduced as “the most advanced digital microscope and fully integrated bench-top platform” in UNITAID’s report in 2022.

Website https://noul.kr/en/

PR Newswire

IHH Healthcare Selects Oracle Exadata Platform to Improve Operational Efficiency and Patient Outcomes

Leave a comment

One of the world’s largest integrated healthcare providers harnesses the power of cloud across Singapore and Malaysia to improve operational efficiency

SINGAPORE, April 17, 2024 /PRNewswire/ — Oracle CloudWorld Tour Singapore — IHH Healthcare (IHH), a world-leading integrated healthcare provider, has selected Oracle Exadata Database Service running on the Oracle Exadata platform to modernize its operations in Singapore and Malaysia, aiming to improve patient services, while maintaining the highest level of patient privacy. To meet the unique local market and regulatory needs, IHH Singapore has migrated its core application workloads to Oracle Exadata Database Service on Oracle Cloud Infrastructure (OCI), while IHH Malaysia migrated its database workloads to Oracle Exadata Cloud@Customer.

IHH is one of the world’s largest healthcare networks with more than 80 hospitals across 10 countries including Singapore and Malaysia. IHH needed a robust database platform to manage massive amounts of data, keep it secure, and use it to improve patient outcomes. IHH Singapore migrated its core application workloads to Oracle Exadata Database Service on OCI including its Electronic Medical Records used by IHH Singapore’s more than 5,000 staff to support its patients, enterprise data warehouse and laboratory information systems. Meanwhile, IHH Malaysia consolidated and migrated its database workloads including its patient management system, appointment booking system, lab information, and billings to Oracle Exadata Cloud@Customer to meet stringent data residency and compliance requirements. By consolidating its disparate on-premises database systems in the cloud, IHH improves patient and clinician user experiences with faster and more reliable access to secure, up-to-date information.

“IHH Healthcare believes in the transformative power of modern technology to enhance patient outcomes,” said Linus Tham, group chief information officer, IHH Healthcare. “With the support of Oracle Exadata Database Service on the Exadata platform in Singapore and Malaysia, we are able to leverage cloud benefits while complying with local regulatory requirements. This migration marks a significant step towards establishing a unified digital healthcare ecosystem, crucial for dismantling data silos, and enhancing data analytics capabilities for our physicians. By alleviating administrative burdens, our physicians can dedicate more attention to patient care. This also aligns with our strategy to use innovative technologies such as AI to deliver world-class healthcare services.”

Oracle Exadata Database Service delivers the versatility of Oracle Database on purpose-built, optimized infrastructure deployed on public and hybrid clouds. Built-in cloud automation, elastic resource scaling, security, and fast performance for all Oracle Database workloads help simplify management and reduce costs. IHH selected the Oracle Exadata platform on OCI and Cloud@Customer deployments for its scalable high performance and integrated high availability, data protection, security, and disaster recovery capabilities which are critical to support continuous operations.

“Today’s healthcare organizations must manage massive amounts of data, keep it secure, and use it to improve patient outcomes, all while keeping costs under control,” said Chin Ying Loong, regional managing director, ASEAN & South Asia Growing Economies (SAGE), Oracle. “Cloud technology serves as the cornerstone for the future of healthcare, facilitating collaboration and unifying data across the healthcare ecosystem. As the need to analyze data in real-time intensifies, the Oracle Exadata platform can provide the industry with high performance database services on OCI or Cloud@Customer options to store, process, and protect patient data.”

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com.

About Oracle CloudWorld Tour
Oracle CloudWorld Tour is Oracle’s global celebration of customers and partners. Join us to discover the insights you need to tackle your biggest business challenges, build your skills, knowledge, and connections, and learn more about our cloud infrastructure, database, and applications from the people that build and use them. For live keynotes, session details, news and more visit oracle.com/sg/cloudworld-tour/ or oracle.com/apac/news.

Trademarks
Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

About IHH Healthcare 
A world-leading integrated healthcare provider, IHH believes that making a difference starts with our aspiration to Care. For Good.  

Our team of more than 70,000 people commit to deliver greater good to our patients, our people, the public and our planet, as we live our purpose each day to touch lives and transform care. 

Through our portfolio of trusted brands – Acibadem, Mount Elizabeth, Prince Court, Gleneagles, Fortis, Pantai and Parkway – we offer our patients comprehensive and personalised care ranging from primary to quaternary, and even ancillary services such as laboratory, diagnostics, imaging and rehabilitation. 

With our scale and reach in 10 countries, we continue to raise the bar in healthcare in our key markets of Malaysia, Singapore, Turkiye, India, Greater China (including Hong Kong), and beyond.

In partnership with our stakeholders, we will co-create a sustainable future for all as we work towards our vision to be the world’s most trusted healthcare services network. 

More information can be found at www.ihhhealthcare.com.

PR Newswire

Hanvon Technology Launches Groundbreaking Fourth-Generation BP Meter Based on Korotkoff Sound Method

Leave a comment

A World Health Organization report highlights that a third of the global adult population suffers from hypertension, with nearly half undiagnosed due to inadequate blood pressure meters, posing significant health risks.

BEIJING, Feb. 28, 2024 /PRNewswire/ — Hanvon Technology Co., Ltd., based in China, has launched the world’s first smart electronic BP Meter utilizing the Korotkoff sound method. This device integrates advanced sensor technology with artificial intelligence algorithms, overcomes the accuracy limitations of traditional electronic BP Meter, and achieves the precision of mercury sphygmomanometers; it starts a new era of Electronic BP Meters.


Inaccurate blood pressure measurement will lead to misdiagnosis or missed diagnosis of hypertension, even inappropriate treatment and cardiovascular disease risks. BP Meter with high accuracy is important to hypertension patients.

The Korotkoff sound method, developed by Russian physician Nikolai Korotkoff in 1905. Place a stethoscope at the underpart of the cuff; increase the cuff pressure to block blood; hear the impact sound of blood against the blood vessels (that is the Korotkoff sound) through the stethoscope during the cuff pressure drops to measure the blood pressure. Korotkoff sound method is considered as the gold standard of NIBP. However, its use is declined due to complexity and mercury risks. Most current electronic BP Meters use the oscillometric method to estimate blood pressure with oscillatory wave, which have big deviation.

Hanvon’s BP Meter bases on the Korotkoff sound method，uses proprietary pressure and piezoelectric sensors to accurately detect arterial position and sound wave changes from blood flow, utilizing a neural network-based deep learning model for precise systolic and diastolic pressure measurements and automatic categorization of blood pressure characteristics for personalized management. This simplifies the measurement process and ensure accurate data collection.

Clinical tests show Hanvon’s device achieves a mean difference of ±1 mmHg and a standard deviation of ±2 mmHg, significantly exceeding the ISO 81060-2:2018 standard, which allows a mean difference of ±5 mmHg and a standard deviation of ≤±8 mmHg. This precision offers healthcare professionals and patients reliable blood pressure information, help improving treatment outcomes and reducing potential risks associated with inaccuracies of oscillometric method, fix a major clinical challenge, and will provide significant impact for effective hypertension management.

Hanvon BP Meter with Korotkoff sound method is now available in China mainland, and is expected to enter the international market in the near future.

PR Newswire

Zepp Health Unveils Zepp OS 3.5 with Zepp Flow™, Powered by Large Language Model AI, Pioneering the Next Generation of Wearable Intelligence Devices at MWC Barcelona 2024

Leave a comment

MILPITAS, Calif., Feb. 26, 2024 /PRNewswire/ — Zepp Health Corporation (“Zepp Health”) (NYSE: ZEPP), a global leader in smart wearables and health technology, today announces a significant stride in wearable intelligence with the introduction of Zepp OS 3.5, featuring Zepp Flow™. This revolutionary enhancement brings a whole new level of interaction to wearable devices, marking a pioneering advancement in the industry, making Zepp Health’s Amazfit smartwatches the first to have a fully integrated Natural-Language User Interface (LUI) powered by LLM AI in its operating system.

Zepp Flow™, the centerpiece of Zepp OS 3.5, represents much more than just a voice assistant; it embodies a paradigm shift in user experience. Inspired by the concepts of balance and harmony, the name “Flow” encapsulates the smooth and intuitive nature of user interaction. Much like the effortless movement of water or the focused energy experienced in a state of “flow,” Zepp Flow™ facilitates a seamless connection between users and their devices, allowing for natural, uninterrupted interaction.

Designed to understand natural language, Zepp Flow™ eliminates the need for predefined commands or keywords, enabling users to express their intentions freely. By intuitively interpreting user requests, whether it’s initiating a workout or managing daily tasks, Zepp Flow™ streamlines the user experience, making it more intuitive and effortless than ever before. This breakthrough represents a significant leap towards a future where artificial intelligence seamlessly integrates into everyday life, particularly in health, fitness, and productivity domains.

A Future of Connectivity and Intelligence

With a global presence spanning over 90 countries and a user base exceeding 42 million, Zepp Health, through its renowned brands like Amazfit, is committed to redefining the way individuals approach their health and wellness. By harnessing advanced technology and fostering collaboration across its brand portfolio, Zepp Health is at the forefront of innovation, shaping the future of wearable technology.

Through Zepp Flow™, Zepp Health continues to push the boundaries of wearable technology, empowering users to seamlessly integrate smart devices into their daily lives. Zepp Flow™ represents a significant milestone in wearable intelligence, embodying the seamless integration of AI into people’s everyday lives. “With dedicated R&D teams across North America, Europe, and Asia, we are committed to driving innovation and delivering unparalleled user experiences, to bring intelligent healthcare solutions empowering people to take control of their well-being,” said Wayne Huang, CEO of Zepp Health. He added, “Zepp Flow™ epitomizes our dedication to unified connectivity and intelligent functionality throughout our ecosystem. Expanding its reach from the Zepp OS on smartwatches to the Zepp App on smartphones, and integrating with natural language processing, Zepp Flow™ asserts itself as the omnipresent AI within our system. Whether it resides on your smartwatch, earbuds, our app on your phone, or in the cloud, Zepp Flow™ guarantees a seamless and intuitive experience across all platforms.”

How Zepp Flow™ Works

Zepp Flow™ boasts several key features that redefine user experience:

  1. Natural Conversation: Unlike traditional voice assistants, Zepp Flow™ allows users to express themselves freely without requiring specific command phrases.
  2. Efficient Recognition: Zepp Flow™ rapidly and accurately recognizes user speech, ensuring a smooth and responsive interaction.
  3. Precise Understanding: Users need only describe what they want, and Zepp Flow™ will recognize their intent and provide the most appropriate response.

Availability

  • Zepp OS 3.5 and Zepp Flow™ will be supported on the Amazfit Balance in the US, Canada, United Kingdom and Republic of Ireland, via a firmware update on February 26th.
  • Amazfit Balance users in France, Italy, Germany, Spain, Liechtenstein, Luxembourg, Monaco, Switzerland, Andorra, Austria, Belgium, and San Marino will be able to upgrade to Zepp OS 3.5 on May 1st.
  • The Amazfit Cheetah series, Amazfit Falcon, and Amazfit T-Rex Ultra will receive this update on a rolling basis, starting from May 28th through until June 11th. The Amazfit Active will be upgraded on June 20th.

About Zepp Health Corporation

Zepp Health (NYSE:ZEPP), a global smart wearable and health technology leader, empowers users to live their healthiest lives by optimizing their health, fitness, and wellness journeys through its leading consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. Powered by its proprietary Zepp Digital Health Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, it delivers cloud-based 24/7 actionable insights and guidance to help users attain their wellness goals. To date, Zepp Health has shipped over 200 million units and its products are available in 90+ countries. Founded in 2013, Zepp Health has offices across the Americas, EMEA, and APAC regions. For more information, visit www.zepp.com. 

PR Newswire

China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI

Leave a comment

Establishing a comprehensive “AI-assisted Physician” using generative AI from Google Cloud, including MedLM

TAICHUNG, Feb. 17, 2024 /PRNewswire/ — China Medical University Hospital (CMUH) in Taiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud’s generative AI technology, including MedLM, which is a large language model built on Med-PaLM 2, CMUH has developed a comprehensive “AI-assisted Physician” system which aims to assist healthcare professionals in disease diagnosis, treatment planning, patient education, and medical research, etc. 

Superintendent Der-Yang Cho of CMUH announced a collaboration with Google Cloud to develop a large language model, MedLM, based on Med-PaLM 2. CMUH is the first medical center in Asia to adopt Med-PaLM 2.
Superintendent Der-Yang Cho of CMUH announced a collaboration with Google Cloud to develop a large language model, MedLM, based on Med-PaLM 2. CMUH is the first medical center in Asia to adopt Med-PaLM 2.

The collaboration between CMUH and Google Cloud will introduce assistive tools designed to support medical professionals in precision cancer treatment. These tools, including “Customized Cancer Treatment Guidelines” and “Cancer Therapy Q&As,” aim to reduce the time spent searching for information and enable the quick capture of accurate data. This can aid professionals in developing cancer treatment plans, offering personalized treatment-related information to patients, and providing responses to patient health education inquiries.

CMUH is one of the first university hospitals in Asia to test MedLM. Through its collaboration with Google Cloud, CMUH is dedicated to driving AI innovation in smart healthcare to shape the future of healthcare in Taiwan. MedLM will help facilitate CMUH in the timely access of accurate medical information to establish the best Healthcare AI models for the Chinese-speaking market in Asia.

Prof. Der-Yang Cho, Superintendent of CMUH, pointed out that MedLM is advanced in its ability to provide precise and rapid data analysis for drug guidelines, disease gene sequencing, and medical records, among other areas. Such capabilities can significantly accelerate the discovery of new treatments for difficult-to-treat diseases by medical teams and assist in the rapid development of treatment plans to help patients. “We are excited about this collaboration, which positions smart hospitals in Taiwan at the forefront of providing more precision- and safety-oriented support to healthcare professionals and patients alike,” Prof. Der-Yang Cho said.

CMUH was already recognized as the world’s third smart hospital by the US. Healthcare Information and Management Systems Society (HIMSS) in their 2022 Digital Health Indicator (DHI) ranking. Additionally, Newsweek named CMUH as one of the World’s Best Hospitals for 2023 and one of the World’s Best Smart Hospitals for 2024. With its widespread recognition, CMUH is deeply committed to advancing the diversification and precision of smart healthcare services.

“Life sciences problems are fundamentally data problems, and this is where AI can fully unleash its potential,” said Kathy Lee, Managing Director of Google Cloud, North Asia. “Generative AI solutions from Google Cloud can help healthcare and life sciences organizations operate more efficiently and improve patient outcomes. In this remarkable era of gen AI, we are excited to collaborate with medical industry leaders that drive innovation through AI like CMUH, and partner with them to build the future of healthcare in Taiwan.”

Aashima Gupta, Global Director of Healthcare Strategy and Solutions at Google Cloud, shared that healthcare professionals are committed to delivering the best care for patients, and gen AI can be a crucial ally in reducing their workload. Gupta pointed out that this technology will ease the cognitive burden for staff and improve personal care for patients. Furthermore, it will allow healthcare professionals at CMUH to devote more time to tasks that require human judgment and expertise. She mentioned that ensuring the safety and effectiveness of gen AI is fundamental to these benefits.

Greg Corrado, a Distinguished Scientist and Senior Research Director at Google Research, discussed how MedLM is designed specifically for the healthcare industry and is part of the growing family of gen AI technologies that have the potential to significantly improve the healthcare experience for professionals and patients. Corrado emphasized the importance of collaborating with healthcare institutions like CMUH in testing and implementing new gen AI solutions, underlining it as a critical step towards developing safe and effective AI technologies.

Prof. Oscar K. Lee, Vice Superintendent of CMUH explained that among global generative AI large language models, Med-PaLM 2 stands out in model performance. It scored 85% on MedQA-USMLE (US Medical Licensing Examination), reaching a level of excellence comparable to professional physicians. This makes it a pioneer among the world’s medical AI models in terms of outstanding performance. By training the model to analyze treatment guidelines and care cultures from various regions, MedLM will become even better at addressing the medical and healthcare needs of local populations.”

Currently, the collaborative applications between CMUH and Google Cloud include “Customized Cancer Treatment Guidelines” and “Cancer Therapy Q&As”. The “Customized Cancer Treatment Guidelines” are developed based on the National Comprehensive Cancer Network (NCCN) guidelines and are integrated with MedLM, enabling clinicians to quickly capture accurate information based on the patient’s cancer staging, treatment methods, and risk assessments, etc. It can also generate cancer treatment plans and provide personalized treatment recommendations for clinicians to review, edit and use with patients. Focusing on health education for cancer patients, the “Cancer Therapy Q&As” application incorporated the cancer care-related health educational content of CMUH into the MedLM model for training and optimization, resulting in a system with extensive medical knowledge and Q&A capabilities. Such advancement not only diminishes the time healthcare professionals spend searching for information but also provides comprehensive treatment options. Furthermore, it contributes to enhancing overall clinical efficacy, improving patient understanding and engagement, and enhancing the quality of healthcare, thereby fostering warmer doctor-patient interactions and steering us collectively toward a healthier future.

In addition, in terms of new drug development, CMUH is leveraging Google’s unique AI accelerators, TPU (Tensor Processing Unit), to assist in calculations related to protein folding and the development of new drugs. Preliminary tests at CMUH have shown that utilizing these resources can reduce the computation time for related programs by over tenfold.

With its robust research and development capabilities, CMUH’s Artificial Intelligence Center has provided over 20 distinct AI medical services in recent years, assisting doctors in making fast and accurate medical decisions.

Media contact: Carolyn Chen, 100709@tool.caaumed.org.tw

PR Newswire

Mindvalley Launches First Fully Immersive Meditation and Personal Development App on Apple’s Vision Pro

Leave a comment

Mindvalley is solo immersive Personal Development App Included on visionOS App Store 

KUALA LUMPUR, Malaysia and LONDON and NEW YORK and LOS ANGELES, Feb. 3, 2024 /PRNewswire/ — Mindvalley, the leading personal growth platform, is thrilled to announce the launch of its groundbreaking fully immersive meditation and personal development app on Vision Pro, Apple’s revolutionary spatial computing headset.

Mindvalley Vision Pro Launch

The app, jointly developed by Mindvalley and Oscar-winning creative studio, Framestore, represents a major breakthrough in personal development. With the integration of state-of-the-art virtual reality and audio technologies, users can now experience fully immersive meditations in breathtaking natural environments such as forests, deserts, and mountains. Additionally, the app offers a unique feature allowing users to practice and improve their public speaking skills through fully immersive simulations, in addition to Mindvalley’s extensive library of episodic personal growth content; Quests.

“We are incredibly excited about this collaboration with Apple,” said Vishen, Founder and CEO of Mindvalley. “Mindvalley was founded to help people push the boundaries of innovation and personal growth. By combining our passion for transformation with Apple’s cutting-edge technology, this app has the potential to revolutionize the way people approach meditation and personal growth.”

The collaboration between Mindvalley and Apple at the Vision Pro Developer Labs brought together two innovative forces in their respective industries. Mindvalley, known for its expansive library of online courses and programs, has impacted over 20 million lives worldwide by helping individuals unlock their full potential. Apple, renowned for its commitment to revolutionizing technology and creating seamless user experiences through its range of products and services, is on a continuous path of innovation.

As part of the Developer Labs, Mindvalley worked closely with Apple Worldwide Developer Relations in Singapore to integrate Vision Pro’s extraordinary capabilities with Mindvalley’s transformational content. Vision Pro offers high-quality displays, immersive environments, spatial audio, and advanced eye tracking, which were incorporated into the Mindvalley app to ensure an unparalleled level of immersion and interactivity.

“It was an honor to work with Apple’s amazing team in Singapore to gain unprecedented access to the Vision Pro as we developed the app,” said Manon Dave, Chief Product Officer of Mindvalley and Creative Technology Director at Framestore. “Vision Pro is the next step in personal computing, and we’re thrilled to have worked with Apple to bring Mindvalley to the forefront of wellness tech.”

To bring the experiences on the app to life, Mindvalley enlisted Framestore’s world-leading VFX and Immersive talent. “We are immensely proud to have collaborated with Mindvalley to bring forth a transformative experience for their users,” said Framestore CEO Mel Sullivan. “Partnering to integrate the unique capabilities of Apple Vision Pro was an extraordinary opportunity for our immersive team, leveraging our expertise honed in crafting world-class visuals for every screen. This project underscores our commitment to push the boundaries of technology while highlighting how innovation can be used to create a meaningful and impactful experience that resonates with people on a profound level.”

For more information about Mindvalley and their upcoming immersive app on Vision Pro, visit their website at www.mindvalley.com.

About Mindvalley:
Mindvalley is the world’s most powerful transformation platform that helps people step into their greatness. From longevity and wellness, to peak performance and spirituality, we provide cutting-edge programs from leading experts to help people achieve success and happiness and find fulfillment. Mindvalley’s learning platform, called ‘Quest’, introduces a new way of learning that delivers unparalleled results in human transformation. Mindvalley reaches more than 195 countries and has a vibrant community of 20 million passionate followers, boasting over 19,000 success stories and counting. Follow Mindvalley for more life-changing content at mindvalley.com or on social media: Instagram, Facebook, YouTube and TikTok.

About Framestore:
Framestore is a multi Academy Award-winning creative studio that combines talent and technology to reframe the possible in film, content, advertising and immersive experiences. Framestore is home to over 3,000 storytellers and innovators, united by a mission to bring life to everything they create. Founded in the UK in 1986, Framestore has studios in New York, LA, Chicago, Montreal, Vancouver, London, Melbourne and Mumbai.

Video – https://mma.prnasia.com/media2/2333273/Mindvalley_Vision_Pro_Launch_Sizzle.mp4

https://mma.prnasia.com/media2/2333273/Mindvalley_Vision_Pro_Launch_Sizzle.mp4
PR Newswire

PranaQ to Unveil Revolutionary Sleep Tech at CES 2024: Introducing TipTraQ, the AI Sleep Tracking and Improvement Solution

Leave a comment

NEW YORK, Jan. 16, 2024 /PRNewswire/ — PranaQ, the innovative sleep tech startup, has made waves at CES 2024 with the highly anticipated launch of its flagship product, TipTraQ. This cutting-edge device goes beyond traditional sleep monitoring, offering a comprehensive solution for diagnosing and monitoring respiratory sleep disorders, including sleep apnea, and improving sleep as a whole.

GenAI-Powered Sleep Improvement Program
TipTraQ goes beyond basic sleep monitoring by analyzing user-specific sleep trends, offering real-time tracking, and providing a personalized sleep coaching program powered by GenAI. PranaQ’s sleep improvement program not only tailors recommendations based on the individual’s data but also utilizes this information to find and direct users to the most beneficial treatment and solution options.

Medical-Grade Accuracy Validated by Leading US Medical Institutes
Rigorous testing and verification by leading medical institutes have confirmed the device’s exceptional precision in sleep breathing (including snoring) analysis, sleep stage assessment, and total sleep time tracking. PranaQ is proud to bring medical-grade sleep monitoring to consumers with TipTraQ.

Designed for Comfort and Everyday Use
TipTraQ blends cutting-edge functionality and user-centric design, creating a sleep-tracking solution pivotal for a connected and health-conscious future. Its ergonomic curve ensures comfort and signal quality, complemented by a featherlight design for daily use and an anti-slip strap for universal fit. Featuring eco-friendly components like a rechargeable battery and replaceable strap designed for long-term use, TipTraQ also serves as a key technology enabler for Smart Sleep and telehealth applications.

The Future of Sleep Tech at CES 2024
At CES 2024, PranaQ is proud to have showcased how TipTraQ helps consumers track and improve sleep and inspired them with a glimpse of firsthand experience of the future of sleep technology. With the partnership conversations that started at CES 2024 in Las Vegas, PranaQ can’t wait to collaborate with the sleep and wellness solution experts who showed an unshakable commitment to sleep health towards a common vision: help more people unlock their best sleep.

Media Engagement
For exclusive interviews, review units, demos, or additional information, please contact Alexandra Jones-Kuo at alexandra.joneskuo@pranaq.com

Stay updated on PranaQ’s sleep health journey and receive updates by subscribing to their newsletter or following them on LinkedIn and Instagram.

About PranaQ
PranaQ is committed to the future of IoMT and digital healthcare. We focus on patient-centric solutions and user wellness advocacy, supported by AI-powered wearable technology. Our goal is to empower people to gain more knowledge of their health conditions, more control of their medical treatments, and to improve their quality of life. For more information, visit https://pranaq.com.

PranaQ launches TipTraQ, its award-winning sleep tracking and improvement solution that features medical-grade accuracy and a personalized sleep coaching program powered by GenAI, at CES 2024.
PranaQ launches TipTraQ, its award-winning sleep tracking and improvement solution that features medical-grade accuracy and a personalized sleep coaching program powered by GenAI, at CES 2024.

PR Newswire

RingConn Smart Ring Impresses at CES 2024: Unveiling Plans on Features and Medical Algorithms Updates that Redefine Personal Health Management

Leave a comment

Boasting 24/7 health monitoring with superior comfort and accuracy, the smart ring underlies RingConn’s commitment to advancing the intersection of healthcare and technology

LAS VEGAS, Jan. 13, 2024 /PRNewswire/ — RingConn, a leading personal health technology company, left an indelible mark with its beta presentation and received enthusiastic response from attendees at CES 2024. The brand unveiled a comprehensive plan for the upcoming year, emphasizing product development and advanced medical algorithm updates.

The RingConn booth in LVCC North Hall was a buzz of activity, drawing attention from 100+ top-tier media outlets and influencers. This acclaim was paralleled by the interest of the diverse CES audience, many of whom were introduced to the ring, gaining insights into the brand’s ambitious vision and discovering the profound impact of its technology on personal health management. The event marked a resounding success, with the revolutionary product capturing attention and receiving acclaim from media representatives, industry analysts, distributors, and consumers.


RingConn’s CES Debut Gaining Massive Attention

The CES 2024 exhibition represents a significant milestone for RingConn. Its innovative product garnered the attention of journalists of international top-tier media as well as influencers. Already experienced with a wide array of technology innovations, they were deeply impressed by the ring’s form factor, long battery life, and exceptional tracking capabilities. They were amazed to see how RingConn managed to pack advanced sensors into such a small ring, weighing only 3 to 5 grams.

The ring has also attracted distributors from across the globe who recognized the RingConn Smart Ring as a mature form of health tracker and showed strong interest in forming partnerships.

Some of the visitors are one of the RingConn users community, who were once users of smartwatches. For them, the RingConn Smart Ring marks a refreshing approach to health tracking. Compared with wrist-worn devices, it is a much more discreet and lightweight wearable that seamlessly integrates into their everyday lives. Thanks to the 7-day battery life, they no longer need to leave the ring on the charging pad every night.

“The warm support and acclaim we received at CES 2024 are undoubtedly a confidence booster for the team,” said Dr. Tony Wu, co-founder of RingConn. “At RingConn, we are not merely providing solutions for personal health management; we are creating the means for users to proactively improve their well-being.”


Premium Health Features Rolling Out in 2024

At CES, RingConn shared its latest progress in the development of new features, including menstrual cycle tracking and OSAHS (Obstructive Sleep Apnea Hypopnea Syndrome) monitoring. These two premium features are designed for users with specific needs and are expected to launch for beta testing in Q1 and Q2 of 2024.

Currently, RingConn has already submitted FDA clearance for the ring’s pulse oximeter and OSAHS monitoring feature. Therefore, users who suffer from sleep apnea can take preemptive measures before the situation deteriorates. RingConn expects to receive these two FDA clearances by the end of this year. RingConn will establish the ring as a trustworthy device for consumers and even medical professionals. In addition, the team has achieved significant advancements in cuffless blood pressure monitoring, with this feature set to be released in the upcoming year.

Since its global debut, RingConn has provided tailored, professional health services for tens of thousands of users within a year, who have spoken highly of the ring’s comprehensive tracking capabilities and the user-friendly accompanying app. Looking ahead, RingConn aims to provide refined solutions to health management through constant hardware and software updates.



About RingConn

Established in 2021, RingConn is a leading personal health technology company dedicated to creating innovative products and services that transform the experience of maintaining personal wellness. Guided by the principle of “Hardware + Software + Services,” RingConn aims to become the driver of proactive health management and empower users worldwide by offering a comprehensive and holistic understanding of their well-being.


Media Contact:
Name: Tony WU
Email: tony.wu@ringconn.com
Phone: +86 136 3257 8986

PR Newswire

Merck Collaborates with Acceleration Consortium on Open-Sourcing AI-Driven Experimentation Planner

Leave a comment
  • Bayesian optimization engine that already powers dozens of use cases at Merck now open sourced to foster adoption
  • Close partnership to enable the self-driving labs of tomorrow

DARMSTADT, Germany, Dec. 6, 2023 /PRNewswire/ — Merck, a leading science and technology company, and the Acceleration Consortium, based at the University of Toronto, Canada, today jointly announced that their AI-driven experimentation planner Bayesian Back End (BayBE) is now available open-source on GitHub, with an unrestricted Apache 2.0 license. The joint open-source initiative combines the Merck portfolio of use cases with the Acceleration Consortium’s world-leading excellence in self-driving labs.

“The release and maintenance of open-source code for scientific discovery is imperative for the advancement of self-driving labs. This collaboration moves the needle of multi-stakeholder work in the area of self-driving labs. I am thrilled about our collaboration with Merck on developing and publishing software for AI-assisted experimental planning. As society faces ever-growing challenges, we have no time for science as usual. With this software, we can revolutionize the way experiments are designed and conducted, accelerating discoveries and driving progress in ways we have never imagined before,” said Alán Aspuru-Guzik, Professor of Chemistry and Computer Science at the University of Toronto, and Director of the Acceleration Consortium, which recently launched a seven-year program worth CA$ 200 million, supported by the Canada First Research Excellence Fund.

“This development is a great outcome of our focus on ‘innovation powered by data and digital’. Together with our partners at the Acceleration Consortium, we continue to push productivity with digital tools such as BayBE. Merck continues to invest in digital technologies that can disrupt the healthcare, life science and electronics industries,” said Laura Matz, Chief Science and Technology Officer at Merck. “BayBE unites several advanced technologies under one umbrella and focuses on making them useful for industrial purposes. While it already has many internal use cases, we are excited to share it with a wider community through open source. What started out as a cross-sectorial advancement can now become a cross-industrial one,” Matz continued.

BayBE was built jointly across all three business sectors of Merck. It is a general-purpose toolbox for smart iterative experimentation with emphasis on important add-ons for chemistry and materials science. It enables a more systematic approach by providing recommendations for the next best experiment, leading to better results faster. BayBE can also act as the “brain” for automated equipment, enabling entirely closed-loop self-driving laboratories.

The traditional approach for design of experiments is largely based on intuition and experience of the experimentalist. This can lead to considerable variation between different labs and is particularly challenging for complex campaigns that aim to optimize numerous properties simultaneously. Merck faces these challenges on an every-day basis, for instance as part of experimental optimization campaigns in research, product development and operations. Artificial intelligence (AI) enables novel ways of tackling these problems and reducing the time needed and money spent as well as increasing sustainability.

The BayBE software already powers dozens of use-cases at Merck, for instance:

  • VRP ExcipientFinder: Part of the viscosity reduction platform service of the Life Science business sector of Merck; a tool to accelerate selection of viscosity reducing excipients
  • BayChem: Self-service experimental planner available to everyone at Merck, directly enabling our lab users
  • Self-driving autonomous flow chemistry at Merck: closed-loop platform in the R&D of the Life Science business sector that optimizes chemical reactions fully autonomously

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

PR Newswire

Ubie’s AI Symptom Checker Used by 2 Million Americans in First Year, Fueling Pharma Partnerships

Leave a comment

Ubie, a trailblazing AI-driven healthcare company, has achieved a new milestone with its AI Symptom Checker, surpassing 2 million uses in the U.S. in just over a year. Leveraging this expanding user engagement, Ubie is advancing its partnerships with pharmaceutical companies to promote early disease detection and treatment. Collaborations with industry giants like Takeda, Boehringer Ingelheim, and Pfizer exemplify Ubie’s extensive efforts across a broad range of medical conditions, promoting improved patient care through cutting-edge digital health solutions.

NEW YORK, Dec. 5, 2023 /PRNewswire/ — Ubie, a forerunner in the digital health arena, proudly announces a notable achievement that underscores its commitment to revolutionizing healthcare: Ubie’s AI Symptom Checker has been used more than 2 million times in the U.S. since its introduction to the market just over a year ago. This milestone demonstrates the significant traction the tool has gained among individuals eager to better understand and manage their health.

Since Ubie’s expansion into the U.S. market, the company has been focused on empowering individuals to recognize symptoms early and pursue timely healthcare discussions. This process provides users with in-depth insights into their symptoms, a comprehensive analysis of potential diseases, signs to look out for, and the ideal specialist to consult.

As an evidence-based AI company, data lies at the core of Ubie’s operations and Ubie’s unique relationship with its users allows the collection of differentiated quantitative and qualitative data. Based on user feedback, approximately 75% of patients plan to seek professional medical advice after checking their symptoms with Ubie, reflecting Ubie’s ability to promote high-value care. U.S. user stories illustrate the benefits of Ubie’s AI Symptom Checker:

  • A woman in her 30s, experiencing eye pain and dizziness, utilized the Symptom Checker, which suggested possible health concerns and the importance of a medical assessment. She was later diagnosed with multiple sclerosis (MS), validating the importance of early investigation into her symptoms.
  • An 80-year-old man was prompted by Ubie’s AI to consult a pulmonologist, which led to an early diagnosis of lung cancer, emphasizing the Symptom Checker’s role in early detection.
  • A woman in her 50s was guided by the Symptom Checker to seek medical attention for what turned out to be accurate identifications of bone diseases, highlighting the tool’s effectiveness in early symptom identification.
  • A 60s woman with dizziness mentioned, “The questions you asked matched all of my symptoms. Some I didn’t think to mention to my doctor at the time. I will raise them on my next visit. Thank you.”

Kota Kubo, CEO of Ubie, expresses his enthusiasm: “Surpassing 2 million uses in the U.S. in just a year is more than a number—it’s a marker of our growing role in helping Americans promptly address health concerns and seek professional care. Our technology is designed to complement the work of healthcare providers, bridging the gap from initial concern to professional care.”

Ubie’s collaborations with leading pharmaceutical companies demonstrate the effectiveness of digital health in addressing various medical conditions:

  • In Apr 2023, Ubie partnered with Takeda to tackle Hereditary Angioedema (HAE) through digital transformation initiatives (Press Release).
  • In Mar 2023, Ubie and Pfizer facilitated provider visits for over 17,000 OAB patients in Japan through the integration of “Ubie AI Symptom Checker” and “UUI Consultation Room” (Press Release)
  • In Feb 2022, Ubie worked with Boehringer Ingelheim on a project focused on Pulmonary Fibrosis, enhancing awareness and management of this condition (Press Release).

Recent press releases reflect Ubie’s commitment to enhancing the healthcare experience:

  • The launch of Ubie’s new Generative AI feature for doctors, improving medical record documentation with a 90% User Satisfaction rate (Press Release).
  • Partnership with Google’s Android platform “Health Connect (Beta)” as a launch partner in Japan (Press Release).
  • Successful closure of a $45 million Series C funding round and establish of a New York subsidiary (Press Release).

For more information about Ubie and its AI Symptom Checker, please visit Ubie AI Symptom Checker.

Contact:

Ryosei Hatakeyama
Ubie Inc.
1460 Broadway, New York, NY 10036
Email: pr@ubiehealth.com 

Note to Editors: For more details or to arrange an interview with CEO Kota Kubo, please reach out to Ryosei Hatakeyama at the contact information above.

Source: Ubie, Inc.